Literature DB >> 9726041

Gastrin/cholecystokinin type B receptors in the kidney: molecular, pharmacological, functional characterization, and localization.

A de Weerth1, L Jonas, R Schade, T Schöneberg, G Wolf, A Pace, F Kirchhoff, M Schulz, T Heinig, H Greten, T von Schrenck.   

Abstract

BACKGROUND: Gastrin/cholecystokinin type B receptors (CCKBRs) can be found on parietal cells and smooth muscle cells and are the predominant brain CCK receptors. Recent cloning studies indicate that this is receptor type might also be expressed in the kidney.
MATERIALS AND METHODS: We used Northern blot analysis in guinea pig. kidney and reverse transcriptase polymerase chain reaction (RT-PCR) in several murine kidney cells lines to evaluate this organ for the expression of the CCKBRs. The receptor was pharmacologically characterized by displacement experiments using [125I]-BH-CCKs and various agonists and antagonists. Polyclonal antibodies vs. the CCKBRs were raised in chicken, and immunohistochemistry on tissue sections was used to localize the receptor within the organ. The effect of gastrin on renal cell growth was measured using proximal tubulus (MCT) cells, which were cultured with gastrin (10-9 M) for 24-72 h. Cell counts and [3H]-thymidine incorporation experiments were performed.
RESULTS: CCKBR transcripts can be detected in kidney RNA (tubules > glomeruli > interstitium). RT-PCR revealed CCKBR transcripts in proximal tubules (MCT cells) and in mesangium (MMC). The medullary thick ascending limb of Henle's loop and several control tissues such as liver and muscle were negative. Displacement experiments using [125I]-BH-CCK and various agonists and antagonists identified binding sites with typical CCKBR pharmacology. CCKBRs were localized in the proximal tubulus, distal collecting ducts and mesangium cells. Treatment of rested MCT cells with gastrin 17-1 induced cell proliferation and [3H]-thymidine incorporation by at least 40% compared with normal growth (P < 0.05).
CONCLUSION: These results show for the first time that CCKBRs are present in selected areas of the kidney, and strongly confirm our previous observation that this organ expresses binding sites for [125I]-gastrin. Furthermore, gastrin might act as a growth factor in the kidney.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9726041     DOI: 10.1046/j.1365-2362.1998.00310.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  14 in total

1.  Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis.

Authors:  Yue Chen; Laureano D Asico; Shuo Zheng; Van Anthony M Villar; Duofen He; Lin Zhou; Chunyu Zeng; Pedro A Jose
Journal:  Hypertension       Date:  2013-09-09       Impact factor: 10.190

2.  Expression of cholecystokinin-1 receptor is correlated with proteinuria in human diabetic nephropathy.

Authors:  Mingao Wang; Rujuan Xie; Ruichan Liu; Xibei Jia; Yushi Bao; Xiaomin Liu
Journal:  Endocrine       Date:  2012-03-07       Impact factor: 3.633

3.  Gastrin induces sodium-hydrogen exchanger 3 phosphorylation and mTOR activation via a phosphoinositide 3-kinase-/protein kinase C-dependent but AKT-independent pathway in renal proximal tubule cells derived from a normotensive male human.

Authors:  Tianbing Liu; Pedro A Jose
Journal:  Endocrinology       Date:  2012-12-28       Impact factor: 4.736

4.  Gastrin decreases Na+,K+-ATPase activity via a PI 3-kinase- and PKC-dependent pathway in human renal proximal tubule cells.

Authors:  Tianbing Liu; Prasad R Konkalmatt; Yu Yang; Pedro A Jose
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-01-19       Impact factor: 4.310

5.  Gastrin stimulates renal dopamine production by increasing the renal tubular uptake of l-DOPA.

Authors:  Xiaoliang Jiang; Yanrong Zhang; Yu Yang; Jian Yang; Laureano D Asico; Wei Chen; Robin A Felder; Ines Armando; Pedro A Jose; Zhiwei Yang
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-10-25       Impact factor: 4.310

6.  Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice.

Authors:  Guangchun Jin; Vigneshwaran Ramanathan; Michael Quante; Gwang Ho Baik; Xiangdong Yang; Sophie S W Wang; Shuiping Tu; Shanisha A K Gordon; David Mark Pritchard; Andrea Varro; Arthur Shulkes; Timothy C Wang
Journal:  J Clin Invest       Date:  2009-08-03       Impact factor: 14.808

7.  Altered renal morphology in transgenic mice with cholecystokinin overexpression.

Authors:  Marina Aunapuu; Peeter Roosaar; Tõnu Järveots; Kaido Kurrikoff; Sulev Kõks; Eero Vasar; Andres Arend
Journal:  Transgenic Res       Date:  2008-08-22       Impact factor: 2.788

8.  Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin.

Authors:  Satoshi Miyamoto; Kenichi Shikata; Kyoko Miyasaka; Shinichi Okada; Motofumi Sasaki; Ryo Kodera; Daisho Hirota; Nobuo Kajitani; Tetsuharu Takatsuka; Hitomi Usui Kataoka; Shingo Nishishita; Chikage Sato; Akihiro Funakoshi; Hisakazu Nishimori; Haruhito Adam Uchida; Daisuke Ogawa; Hirofumi Makino
Journal:  Diabetes       Date:  2012-02-22       Impact factor: 9.461

9.  Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice.

Authors:  Erik Vegt; Marleen Melis; Annemarie Eek; Monique de Visser; Maarten Brom; Wim J G Oyen; Martin Gotthardt; Marion de Jong; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-18       Impact factor: 9.236

10.  The Synergistic Roles of Cholecystokinin B and Dopamine D5 Receptors on the Regulation of Renal Sodium Excretion.

Authors:  Xiaoliang Jiang; Wei Chen; Xing Liu; Zihao Wang; Yunpeng Liu; Robin A Felder; John J Gildea; Pedro A Jose; Chuan Qin; Zhiwei Yang
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.